Related Experiment Video
Updated: Jan 19, 2026
Targeted Cancer Therapies: Imatinib Mesylate and Trastuzumab
PLK4: a promising target for cancer therapy
1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, No. 324, Jingwu Road, Jinan, 250021, Shandong, People's Republic of China.
Polo-like kinase 4 (PLK4) regulates cell division and is crucial in cancer development. PLK4 inhibitors show promise as a targeted cancer therapy, alone or in combination treatments.
Area of Science:
- Molecular Biology
- Cancer Biology
- Cell Biology
Background:
- Polo-like kinase 4 (PLK4) is a key regulator of centriole duplication.
- Deregulation of PLK4 leads to centrosome abnormalities, impacting cell division and genomic stability.
- PLK4 dysfunction is implicated in tumorigenesis, making it a significant therapeutic target in oncology.
Purpose of the Study:
- To review the critical role of centrosome amplification and PLK4 in cancer progression.
- To highlight recent advancements in the development of PLK4 inhibitors.
- To discuss potential combination therapies involving PLK4 inhibition for cancer treatment.
Main Methods:
- Comprehensive literature review of PubMed.
- Search of ClinicalTrials.gov for relevant clinical trials.
Main Results:
- Aberrant PLK4 expression is observed across various cancers and holds prognostic significance.
- Inhibition of PLK4 effectively suppresses tumor growth in both in vitro and in vivo models.
- PLK4 inhibitors demonstrate potential as a therapeutic strategy.
Conclusions:
- PLK4 is integral to centrosome amplification and cancer progression.
- PLK4 inhibitors exhibit significant anticancer efficacy, supporting their use as monotherapy or in combination regimens.
- Clinical trial outcomes for PLK4-targeted therapies are pending evaluation.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
08:45Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring
08:09Tubal Cytology of the Fallopian Tube as a Promising Tool for Ovarian Cancer Early Detection